EUVIMEDOpdag EUVIMED
Multizentrische Studie

Incidence of Chronic Rhinosinusitis in Patients Who Receive Rituximab

Kendra Walker, Bastien A Valencia-Sanchez, Prishae Wilson, Natasha Najmi, Angela M Donaldson iD

Otolaryngology–Head and Neck Surgery · 2026-08-17

DOI: 10.1002/ohn.70390 ↗

At a glance

Multizentrische Studie in Otolaryngology–Head and Neck Surgery, published online on 2026-08-17. Written by Kendra Walker and 4 co-authors. Institution: Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic Florida, Jacksonville, Florida, USA. Major MEDLINE topics: Immunologic Factors, Rhinosinusitis, Rituximab. 16 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Objective

Rituximab causes B‐cell depletion and hypogammaglobulinemia, increasing risk for infections. This study aims to determine the incidence of chronic rhinosinusitis (CRS) in patients following rituximab therapy. Study Design Retrospective cohort study using chart review of patients prescribed rituximab between January 2019 and January 2025.

Setting

Multisite study across Mayo Clinic Enterprise locations in Arizona, Florida, Minnesota, and Wisconsin.

Methods

Patients with documented rituximab use were included; those with pre‐existing CRS were excluded. Demographic and clinical data—including timing and duration of rituximab therapy, CRS diagnosis, comorbidities (asthma, allergic rhinitis, GERD), and need for sinus surgery—were collected. Descriptive statistics summarized patient characteristics. Group comparisons were performed using t ‐tests, Mann‐Whitney U , and chi‐square tests. Analyses were conducted using SPSS v28.

Results

Among 17,851 patients prescribed rituximab (median age 64.0 years, M:F ratio 1.1:1), 1105 (6.2%) developed CRS, with an annual incidence of 1.03% (1032 cases per 100,000 person‐years). The median duration of rituximab therapy for those diagnosed with CRS was 5.9 months (IQR, 0.5‐42.6). Most CRS cases occurred after rituximab discontinuation (62.7%, n = 693) compared to during active treatment (37.3%, n = 412). The median delay between rituximab discontinuation and CRS diagnosis was 17.0 months (IQR, 4.3‐41.7).

Conclusions

This study demonstrates an annual incidence of 1.03% for CRS diagnoses following rituximab. While prior studies report varying CRS incidences in the general population (0.25%‐0.73%), our findings suggest increased risk among rituximab users. Most CRS diagnoses occurred after rituximab discontinuation, emphasizing the need for a comprehensive medication history review during CRS evaluation.

Subjects

MeSH terms (MEDLINE)

Immunologic FactorsRhinosinusitisRituximabAgedFemaleHumansMaleMiddle AgedChronic DiseaseIncidenceRetrospective Studies

Author keywords

chronic rhinosinusitisimmunosuppressionincidencerituximab

Substances

Immunologic FactorsRituximab

Authors and institutions

  • Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic Florida, Jacksonville, Florida, USA.

ORCID profiles: Angela M Donaldson

Cite

APA

Walker, K., Valencia-Sanchez, B. A., Wilson, P., Najmi, N., & Donaldson, A. M. (2026). Incidence of Chronic Rhinosinusitis in Patients Who Receive Rituximab. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70390

Vancouver

Walker K, Valencia-Sanchez BA, Wilson P, Najmi N, Donaldson AM. Incidence of Chronic Rhinosinusitis in Patients Who Receive Rituximab. Otolaryngology–Head and Neck Surgery. 2026. doi:10.1002/ohn.70390

BibTeX
@article{Walker2026,
  author = {Walker, Kendra and Valencia-Sanchez, Bastien A and Wilson, Prishae and Najmi, Natasha and Donaldson, Angela M},
  title = {Incidence of Chronic Rhinosinusitis in Patients Who Receive Rituximab},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2026},
  doi = {10.1002/ohn.70390}
}
Start for free →